The EPS beat and strong cash runway are positive, but the stock's move will hinge on APEX Phase 2 Part B data expected in Q2 2026. Monitor for the Part B readout and any updates on asthma/EoE trial designs later this year. The $403M offering was already priced in post-March 2026 readout; near-term focus is on execution toward Phase 3.
Price Chart
Executive Summary
Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenue. The company highlighted durable 52-week Phase 2 data for zumilokibart in atopic dermatitis and a $403M upsized equity offering extending cash runway into 2029. Net loss widened to $74.1M from $55.3M YoY on higher R&D and G&A spend, but the pipeline catalyst (Phase 2 Part B data in Q2 2026 and Phase 3 initiation in 2H 2026) overshadows the loss expansion.
Key Financial Metrics
Key Facts
- EPS of -$1.03 beat consensus of -$1.13 by 9%
- No revenue (pre-commercial biotech)
- Cash position $1.3B as of March 31, 2026, up from $902.9M at Dec 31, 2025, following $403M upsized equity offering
- Net loss widened to $74.1M from $55.3M YoY on higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
- APEX Phase 2 Part A 52-week data showed durable maintenance with 3- and 6-month dosing; 75-85% of Week 16 EASI-75 responders maintained at Week 52
- APEX Phase 2 Part B 16-week data expected in Q2 2026; Phase 3 initiation in AD expected in 2H 2026
- Positive Phase 1b asthma data reported January 2026; expansion into asthma and EoE trials planned later this year
- Cash runway into 2029 supports BLA filing for zumilokibart in AD
Financial Impact
EPS beat of 9% on consensus -$1.13; cash position strengthened to $1.3B from $902.9M
Risk Factors
- Clinical trial failure risk — Part B data may not replicate Part A durability
- Dilution from $403M equity offering already completed; no further near-term dilution expected
- Widening net loss trajectory with no near-term revenue; reliance on capital markets for future funding
- Competitive landscape in AD (DUPIXENT, lebrikizumab, others)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291754 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access